Title: A Clinical Trial of Rosiglitazone Combined with Insulin in the Treatment of Type 2 Diabetic Patients
Abstract: Objective To observe the efficacy and safety of rosiglitazone combined with insulin in the treatment of type 2 diabetic patients who were not good control in plasma glucose on insulin monotherapy. Methods 80 type 2 diabetic patients were randomized into insulin monotherapy group(DM+INS group) 40 cases and rosiglitazone and insulin group(DM+INS+RSG group) 40 cases for 3 months treatment. The dosage of rosiglitazone was given 4mg everyday in DM+INS+RSG group. The changes of laboratory data including fasting plasma glucose(FPG),postprandial plasma glucose(PPG),hemolobulin A1C(HbA1C),cholesteral(TC),triglyceride(TG),high density lipoprotein-cholesteral(HDL-C),low density lipoprotein cholesterol(LDL-C), body mass index(BMI) was measured before and after treatment in different groups. Results There was not significantly difference in FPG,PPG,HbA1C,TC,TG,HDL-C,LDL-C and dosages of insulin in the baselin between DM+INS group and DM+INS+RSG group(P0.05). There was significantly decrease in FPG,PPG and HbA1C in the DM+INS+RSG group after 1 and 3 months treatment(P0.05,P0.01). Conclusion The addition of rosglitazone and insulin can improve the efficacy in glycemic control in the type 2 diabetic patients.
Publication Year: 2008
Publication Date: 2008-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot